EVK has been the subject of a number of other reports. UBS Group set a €27.00 ($33.33) price objective on Evonik Industries and gave the stock a sell rating in a research report on Monday, January 8th. Barclays set a €35.50 ($43.83) price objective on Evonik Industries and gave the stock a buy rating in a research report on Monday, November 6th. DZ Bank restated a buy rating on shares of Evonik Industries in a research report on Wednesday, February 14th. Baader Bank set a €38.00 ($46.91) price objective on Evonik Industries and gave the stock a buy rating in a research report on Thursday, December 14th. Finally, JPMorgan Chase & Co. set a €25.00 ($30.86) price objective on Evonik Industries and gave the stock a sell rating in a research report on Tuesday, November 14th. Three investment analysts have rated the stock with a sell rating, five have given a hold rating and twelve have issued a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and an average price target of €33.79 ($41.72).
Evonik Industries (EVK) opened at €28.84 ($35.60) on Tuesday. Evonik Industries has a 1 year low of €26.78 ($33.06) and a 1 year high of €32.97 ($40.70). The stock has a market capitalization of $13,430.00 and a PE ratio of 18.73.
About Evonik Industries
Evonik Industries AG engages in the specialty chemicals business worldwide. It operates through Nutrition & Care, Resource Efficiency, Performance Materials, and Services segments. The Nutrition & Care segment offers specialty chemicals, including amphoteric surfactants, ceramides, phytosphingosines, oleochemical quaternary derivatives, organically modified silicones, superabsorbents, amino acids and amino acid derivatives, synthesis products, pharmaceutical polymers, and DL-methionine for use in consumer goods, animal nutrition, and healthcare sectors.
Receive News & Ratings for Evonik Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evonik Industries and related companies with MarketBeat.com's FREE daily email newsletter.